Vertex Inaxaplin Reduced Kidney Disease Markers in Trial
The oral therapy demonstrated significant reductions in protein-to-creatinine levels in a mid-stage clinical study.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Should the government prioritize accelerated approval for new drugs targeting rare, underlying genetic diseases?
Vertex Pharmaceuticals reported positive Phase 2b trial results for its investigational drug inaxaplin, which is designed to treat APOL1-mediated kidney disease. The study data confirms the drug's safety and biological activity in a research-stage clinical setting.
Why it matters
This development addresses a targeted therapy need for the roughly 150,000 people in the U.S. and Europe living with APOL1-mediated kidney disease. If confirmed in larger trials, the findings could establish a new standard of care for this patient population.
The 45 mg once-daily oral dose achieved a -42.7% reduction in UACR in Cohort 1 and a -17.3% reduction in Cohort 2 compared to baseline after 13 weeks. No serious adverse events related to the therapy were reported, though headaches occurred in over 5% of the 41 participants.
The players
Vertex Pharmaceuticals
A biotechnology company focused on developing small-molecule drugs for serious genetic diseases, including its pipeline in cystic fibrosis and kidney disease.
The details
Inaxaplin acts as an add-on therapy administered alongside optimized standard of care to target APOL1-mediated kidney disease, a condition driven by genetic variants. The drug works by modulating the function of the APOL1 protein to mitigate damage to the kidney filters, which are responsible for clearing waste from the blood. Researchers measured efficacy using the urine albumin to creatinine ratio (UACR), a standard marker used to estimate the amount of protein leaking into the urine.
Timeline
Week 13: Efficacy endpoints were measured for the AMPLIFIED study.
Early 2027: Interim analysis results for the AMPLITUDE trial are expected.
The Tech Race
The study results represent a data milestone in the broader evaluation of targeted APOL1-mediated kidney disease therapies. The successful enrollment of the separate AMPLITUDE trial confirms that Vertex is maintaining its current clinical development pace.
The therapy is currently in the research stage and not yet available for patient use outside of clinical settings. Future access and clinical availability depend on the successful completion of the AMPLITUDE trial and subsequent regulatory review.
The takeaway
These Phase 2b results suggest that daily oral dosing may effectively address protein markers in APOL1-mediated kidney disease patients. Interested observers should monitor the 2027 interim analysis of the AMPLITUDE trial as a key indicator of potential regulatory progress.
What happens next
Vertex expects to release interim analysis results for the Phase 2/3 AMPLITUDE trial in early 2027, which may support the pursuit of accelerated approval in the United States.
Further reading
Explore the latest developments in Biotech to understand the shifting landscape of genetic therapies.
Live Poll
Should the government prioritize accelerated approval for new drugs targeting rare, underlying genetic diseases?
